Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-31
2007-07-31
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S450000
Reexamination Certificate
active
10202858
ABSTRACT:
A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.
REFERENCES:
patent: 3931397 (1976-01-01), Harnden
patent: 4224404 (1980-09-01), Viza et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4699880 (1987-10-01), Goldstein
patent: 4704692 (1987-11-01), Ladner
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4761375 (1988-08-01), Clark
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5861397 (1999-01-01), Wheeler
patent: 5994317 (1999-11-01), Wheeler
patent: 6022874 (2000-02-01), Wheeler
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 6399588 (2002-06-01), Hobart et al.
patent: 6413942 (2002-07-01), Felgner et al.
patent: 6696424 (2004-02-01), Wheeler
patent: 1 169 793 (1984-06-01), None
patent: 0 027 662 (1981-04-01), None
patent: 0 187 702 (1986-07-01), None
patent: 7 781 (1970-03-01), None
patent: 63-102682 (1988-05-01), None
patent: 63-285738 (1988-11-01), None
patent: 64-47381 (1989-02-01), None
patent: WO 90/01543 (1990-02-01), None
patent: 2135092 (1990-05-01), None
patent: WO 86/00930 (1986-02-01), None
patent: WO 88/05077 (1988-07-01), None
patent: WO 91/07487 (1991-05-01), None
patent: WO 91/16024 (1991-10-01), None
patent: WO 97/19675 (1997-06-01), None
patent: WO 97/37966 (1997-10-01), None
Conry et al., “Safety and immunogenicity or a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients,” Clin. Cancer Res. 8: 2782-2787, Sep. 2002.
Acsadi, G., et al., “Direct Gene Transfer and Expression into Rat Heart in Vivo,”New Biol.3:71-81, W.B. Saunders (Jan. 1991).
Adrian, G.S., et al., “Structure of Adenosine Deaminase mRNAs From Normal and Adenosine Deaminase-Deficient Human Cell Lines,”Mol. Cell. Biol.4:1712-1717, American Society for Microbiology (1984).
Anker, P., et al., “Spontaneous Release of DNA by Human Blood Lymphocytes as Shown in an in Vitro System,”Cancer Res.35:2375-2382, American Association for Cancer Research (1975).
Anker, P., et al., “The Role of Extracellular DNA in the Transfer of Information from T to B Human Lymphocytes in the Course of an Immune Response,”J. Immunogen.7:475-481, Blackwell Scientific Publications (1980).
Anker, P., et al., “Transfert d'information de lymphocytes T à B au cours d'une eŕponse immune: rôle de l'ADN extracellulaire,”Schweiz. med. Wschr.110:1444-1446, Schwabe & Co. AG Verlag (1980).
Anker, P., et al., “Anticorps porteurs d'allotypes humains synthétisés par des souris nues après injection de DNA relâché par des lymphocytes T humains,”Schweiz. med. Wschr.112:1438-1439, Schwabe & Co. AG Verlag (1982).
Anker, P., et al., “Nude Mice Injected with DNA Excreted by Antigen-Stimulated Human T Lymphocytes Synthesize Specific Human Antibodies,”Exp. Cell. Biol.52:133-136, Karger (1984).
Ausubel, F.M., et al., eds., “Vectors Derived from Plasmids. Introduction to Plasmid Biology,” in:Current Protocols in Molecular Biology,Current Protocols, New York, NY, pp. 1.5.1-1.5.3 (1987).
Ausubel, F.M., et al., eds., “Transfection of DNA into Eukaryotic Cells,” in:Current Protocols in Molecular Biology,Current Protocols, New York, NY, pp. 9.1.1-9.1.4 (Mar. 1990).
Bachmann, M.F. and Kündig, T.M., “In vivo versus in vitro assays for assessment of T- and B- cell function,”Curr. Opin. Immunol.6:320-326, Current Biology (Aprl. 1994).
Bains, W., “Antisense,” in:Biotechnology from A to Z,Oxford University Press, New York, NY, pp. 17-19, (Jan. 1998).
Ballas, N., et al., “Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts,”Biochim. Biophys. Acta939:8-18, Elsevier Science Publishers B.V. (1988).
Bangham, A.D., et al., “Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids,”J. Mol. Biol.13:238-252, Academic Press (1965).
Beardsley, T., “Winning Candidate. A painstaking search identifies the gene for cystic fibrosis,”Sci. Amer.261:28-30, Scientific American (Nov. 1989).
Been, M.D. and Cech, T.R., “One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self-Splicing,Trans-Splicing, and RNA Enzyme Activity,”Cell47:207-216, Cell Press (1986).
Behr, J.-P., et al., “Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA,”Proc. Natl. Acad. Sci. USA86:6982-6986, National Academy of Sciences (Sep. 1989).
Brigham, K.L., et al., “Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle,”Am. J. Med. Sci.298:278-281, Lippincott, Williams & Wilkins (Oct. 1989).
Benvenisty, N. and Reshef, L., “Direct introduction of genes into rats and expression of the genes,”Proc. Natl. Acad. Sci. USA83:9551-9555, National Academy of Sciences (1986).
Berge, S.M., et al., “Pharmaceutical Salts,”J. Pharm. Sci.66:1-19, American Pharmaceutical Association (1977).
Bhoopalam, N., et al., “Surface immunoglobulins of lymphocytes in mouse plasmacytoma. IV. Evidence for the Persistence of the Effect of Plasmacytoma-RNA on the Surface Immunoglobulins of Normal Lymphocytes In Vivo and In Vitro,”Clin. Exp. Immunol.23:139-148, Blackwell Scientific Publications (1976).
Bouchard, L., et al., “Tumorigenic Activity of Polyoma Virus and SV40 DNAs in Newborn Rodents,”Virology135:53-64, Academic Press (1984).
Boynton, J.E., et al., “Chloroplast Transformation inChlamydomonaswith High Velocity Microprojectiles,”Science240:1534-1537, American Association for the Advancement of Science (Jun. 1988).
Brock, M.L. and Shapiro, D.J., “Estrogen Stabilizes Vitellogenin mRNA against Cytoplasmic Degradation,”Cell34:207-214, Cell Press (1983).
Brown, D.W. and Robinson, H.L., “Influence ofenvand Long Terminal Repeat Sequences on the Tissue Tropism of Avian Leukosis Viruses,”J. Virol.62:4828-4831, American Society for Microbiology (Dec. 1988).
Brown, M.S. and Goldstein, J.L., “A Receptor-Mediated Pathway for Cholesterol Homeostasis,”Science232:34-47, American Association for the Advancement of Science (1986).
Burmeister, M., et al., “A 10 Meybase pair physical map of Xp21 including the Duchenne muscular dystrophy gene, using PFGE,”Cytogen. Cell Genet.46:589, Karger (1988).
Carmona-Ribeiro, A.M., et al., “Salt Effects on the Stability of Dioctadecyldimethylammonium Chloride and Sodium Dihexadecyl Phosphate Vesicles,”J. Phys. Chem.89:2928-2933, American Chemical Society (1985).
Cech, T.R. and Bass, B.L., “Biological Catalysis by RNA,”Ann. Rev. Biochem.55:599-629, Annual Reviews, Inc. (1986).
Chan, H.W., et al., “Molecular Cloning of Polyoma Virus DNA in
Carson Dennis A.
Felgner Philip L
Malone Robert Wallace
Rhodes Gary H
Wolff Jon A
Priebe Scott D.
Sterne Kessler Goldstein & Fox P.L.L.C.
Vical Incorporated
LandOfFree
Lipid-mediated polynucleotide administration to deliver a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid-mediated polynucleotide administration to deliver a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid-mediated polynucleotide administration to deliver a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3771443